Optimizing the Use of Morphine in Pre-Term Neonates

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to improve the dosing of morphine in critically ill premature neonates.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: John van den Anker
• Collaborators: Erasmus Medical Center; University of Louisville
• Treatments: Morphine

Criteria

Inclusion Criteria:

• Preterm neonates of both genders and all races

• postnatal age less than 30 days

• an indwelling (peripheral or umbilical) arterial line, and

• a clinical indication for intravenous morphine administration

Exclusion Criteria:

• Neonates with severe asphyxia, grade III or IV intraventricular hemorrhage, major congenital malformations/facial malformations, neurological disorders, and those receiving continuous or intermittent neuromuscular blockers.

• clinical or biochemical evidence of hepatic and renal compromise (including systemic hypoperfusion) or

• received drugs that are UGT2B7 substrates (including Lorazepam, ibuprofen, valproic acid, naloxone and other morphine derivatives or propanolol)